Weight Loss Drug Demand Drives Eli Lilly Sales

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker debuted a mostly better-than-expected 2025 forecast.
Eli Lilly beats on earnings even as weight loss, diabetes drug sales fall short
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soared. The company's quarterly earnings topped Wall Street estimates,
Lilly reassures investors that weight-loss drug demand is strong, shares rise
Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.
Eli Lilly records over twofold rise in diabetes/ obesity drugs in Q4
Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight loss and obesity drugs. Read more here.
Eli Lilly’s Disappointing Quarter Was Already Baked In
Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out of the way early. On Thursday morning, when the company formally released its fourth-quarter report,
LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments
Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in
Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars
CNBC's Angelica Peebles joins 'Squawk Box' to report on the company's quarterly earnings results.
Eli Lilly Q4 Earnings: Strong Demand For Mounjaro But Prices Dip, Forecasts Over 30% Jump In 2025 Sales On Newer Medicines
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...
FiercePharma23h
Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound
Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly and Co (LLY) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
Eli Lilly and Co (LLY) reports a 45% increase in Q4 revenue, driven by new products, while outlining ambitious growth and ...
Lilly’s Mounjaro and Zepbound contribute to big revenue boost, drugmaker says
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Eli Lilly price target raised to $1,000 from $997 at BofA
BofA analyst Tim Anderson raised the firm’s price target on Eli Lilly (LLY) to $1,000 from $997 and keeps a Buy rating on the shares after ...